Literature DB >> 30343451

Black pepper and its bioactive constituent piperine: promising therapeutic strategies for oral lichen planus.

Jing-Ya Yang1, Jing Zhang1,2, Gang Zhou3,4.   

Abstract

Oral lichen planus (OLP) is a common T cell-mediated chronic inflammatory disease with malignant potential and unclear etiology. The present study suggests that antigen-specific mechanisms in which dentritic cells, T lymphocytes and NF-κB signaling pathway play critical roles, are involved in the pathogenesis of OLP. Additionally, it has been indicated that altered expression of cyclooxygenase 2 (COX-2) and imbalanced oxidant-antioxidant status as well as psychological issue may act as promoters to the development of OLP. Therapies for OLP are primarily aimed to control symptoms and a specific cure is not yet available. Black pepper and its principle bioactive compound piperine have been reported to possess remarkable pharmacological activities. Not only has piperine been evidenced to exhibit repressive effects on the maturation of dentritic cells, the proliferation, activation and function of T lymphocytes as well as the NF-κB signaling pathway, but also to suppress the overproduction of COX-2 and weaken the oxidative stress. Furthermore, piperine might be a possible agent for alleviating psychological disorders and preventing carcinogenesis. Given all these into consideration, piperine may be a novel and effective therapeutic strategy for OLP.

Entities:  

Keywords:  Black pepper; Oral lichen planus; Piperine

Mesh:

Substances:

Year:  2018        PMID: 30343451     DOI: 10.1007/s10787-018-0540-7

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  117 in total

1.  Characterization of the differentiated antioxidant profile of human saliva.

Authors:  Rafael M Nagler; Ifat Klein; Nataly Zarzhevsky; Noam Drigues; Abraham Z Reznick
Journal:  Free Radic Biol Med       Date:  2002-02-01       Impact factor: 7.376

2.  Matrix metalloproteinases and their inhibitors in oral lichen planus.

Authors:  X J Zhou; P B Sugerman; N W Savage; L J Walsh
Journal:  J Cutan Pathol       Date:  2001-02       Impact factor: 1.587

3.  Anxiety and depression as risk factors for oral lichen planus.

Authors:  M J Vallejo; G Huerta; R Cerero; J M Seoane
Journal:  Dermatology       Date:  2001       Impact factor: 5.366

4.  Autocytotoxic T-cell clones in lichen planus.

Authors:  P B Sugerman; K Satterwhite; M Bigby
Journal:  Br J Dermatol       Date:  2000-03       Impact factor: 9.302

Review 5.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

6.  The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis.

Authors:  L K Myers; A H Kang; A E Postlethwaite; E F Rosloniec; S G Morham; B V Shlopov; S Goorha; L R Ballou
Journal:  Arthritis Rheum       Date:  2000-12

7.  Effects of piperine on antioxidant pathways in tissues from normal and streptozotocin-induced diabetic rats.

Authors:  F M Rauscher; R A Sanders; J B Watkins
Journal:  J Biochem Mol Toxicol       Date:  2000       Impact factor: 3.642

8.  In vitro antioxidant activity of piperine.

Authors:  R Mittal; R L Gupta
Journal:  Methods Find Exp Clin Pharmacol       Date:  2000-06

9.  Psychoneuroimmunology in oral biology and medicine: the model of oral lichen planus.

Authors:  Paolo Prolo; Francesco Chiappelli; Elaina Cajulis; Janet Bauer; Susan Spackman; Horacio Romeo; Marco Carrozzo; Sergio Gandolfo; Russell Christensen
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

Review 10.  The pathogenesis of oral lichen planus.

Authors:  P B Sugerman; N W Savage; L J Walsh; Z Z Zhao; X J Zhou; A Khan; G J Seymour; M Bigby
Journal:  Crit Rev Oral Biol Med       Date:  2002
View more
  1 in total

Review 1.  Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19.

Authors:  Angela E Peter; B V Sandeep; B Ganga Rao; V Lakshmi Kalpana
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.